{"id":1500,"date":"2015-10-28T15:00:02","date_gmt":"2015-10-28T14:00:02","guid":{"rendered":"https:\/\/dev.intervacc.se\/?p=1500\/"},"modified":"2017-02-20T15:21:16","modified_gmt":"2017-02-20T14:21:16","slug":"intervacc-signs-agreement-optimization-manufacturing","status":"publish","type":"post","link":"https:\/\/intervacc.se\/en\/intervacc-signs-agreement-optimization-manufacturing\/","title":{"rendered":"Intervacc signs agreement for optimization of manufacturing"},"content":{"rendered":"<div class=\"preamble\">Intervacc is pleased to announce that an agreement has now been signed with PX\u00b4Therapeutics, Grenoble, France, for process optimization of Strangvac. PX\u00b4Therapeutics, a subsidiary of Aguettant pharmaceutical group, has the experience, facilities and personnel to produce recombinant proteins from E. coli in compliance with GMP.<\/div>\n<p>The aim is to obtain a more efficient and cost effective production of Strangvac<sup>\u00ae<\/sup>, which is composed of three recombinant proteins. Initial work on optimization has already begun and Intervacc foresees a smooth transfer of production technology and analytical procedures associated with the manufacturing process.<\/p>\n<p><a href=\"http:\/\/www.px-therapeutics.com\/\" target=\"_blank\"><img decoding=\"async\" class=\"alignleft wp-image-1487 size-full lazyload\" data-src=\"https:\/\/intervacc.se\/wp-content\/uploads\/2017\/02\/logo_pxt.png\" alt=\"PX-Therapeutics\" width=\"312\" height=\"68\" data-srcset=\"https:\/\/intervacc.se\/wp-content\/uploads\/2017\/02\/logo_pxt.png 312w, https:\/\/intervacc.se\/wp-content\/uploads\/2017\/02\/logo_pxt-300x65.png 300w\" data-sizes=\"(max-width: 312px) 100vw, 312px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 312px; --smush-placeholder-aspect-ratio: 312\/68;\" \/><\/a> <a href=\"http:\/\/www.aguettant.com\/\" target=\"_blank\"><img decoding=\"async\" class=\"alignright wp-image-1488 size-full lazyload\" data-src=\"https:\/\/intervacc.se\/wp-content\/uploads\/2017\/02\/aguettant.png\" alt=\"Aguettant logo\" width=\"125\" height=\"152\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 125px; --smush-placeholder-aspect-ratio: 125\/152;\" \/><\/a><\/p>\n<p style=\"clear: both;\">\n<div style=\"display:flex; gap:10px;justify-content:center\" class=\"wps-pgfw-pdf-generate-icon__wrapper-frontend\">\n\t\t<a  href=\"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/1500\/?action=genpdf&amp;id=1500\" class=\"pgfw-single-pdf-download-button\" target=_blank><img data-src=\"https:\/\/intervacc.se\/wp-content\/plugins\/pdf-generator-for-wp\/admin\/src\/images\/PDF_Tray.svg\" title=\"Generate PDF\" style=\"width:auto; height:45px;\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\"><\/a>\n\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Intervacc is pleased to announce that an agreement has now been signed with PX\u00b4Therapeutics, Grenoble, France, for process optimization of Strangvac. PX\u00b4Therapeutics, a subsidiary of Aguettant pharmaceutical group, has the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[25],"tags":[],"class_list":["post-1500","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/1500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=1500"}],"version-history":[{"count":1,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/1500\/revisions"}],"predecessor-version":[{"id":1502,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/1500\/revisions\/1502"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=1500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/categories?post=1500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/tags?post=1500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}